• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Isentress (raltegravir)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Isentress (raltegravir)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Isentress is an orally available human immunodeficiency virus integrase strand transfer inhibitor. Once a cell is infected with HIV, its RNA must be converted (reverse transcribed) into DNA. Integrase, a viral enzyme, helps to hide HIV's DNA inside the cell's DNA. Integrase inhibitors work by blocking this process, known as integration. Thus, Isentress prevents HIV DNA from entering healthy cell DNA.

    Isentress, in combination with other antiretroviral agents, is specifically indicated for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.

    Isentress is supplied as a tablet designed for oral administration. The recommended initial dose of the drug is 400 mg administered orally, twice daily with or without food.

    Clinical Results

    FDA Approval
    The FDA approval of Isentress is based on the results of two clinical trials. These randomized, double-blind, placebo-controlled trials were dubbed BENCHMARK-1 and BENCHMARK-2. The trials enrolled treatment-experienced HIV-infected subjects who had failed antiretroviral therapies (ARTs), and who had HIV virus resistant to at least one drug in each of the three available classes of oral ARTs. In both studies, subjects received 400mg or placebo, each dosed orally twice daily in combination with OBT. The trials were designed to compare Isentress plus optimized background therapy (OBT) to placebo plus OBT in terms of reduction in HIV viral load, change from baseline in CD4 cell counts and evaluation of safety and tolerability.

    BENCHMARK-1
    This trial enrolled subjects in Europe, Asia and Peru. The mean baseline viral load was 4.6 log10 copies/mL and the mean CD4 cell counts 156 cells/mm3 for the Isentress group and 4.5 log10 copies/mL and 153 cells/mm3, respectively, for the placebo group. In BENCHMARK-1, 77% of subjects receiving Isentress in combination with OBT achieved HIV RNA viral load reduction below 400 copies/mL compared to 41% of subjects receiving placebo plus OBT (p<0.001). In addition, 61% of subjects receiving Isentress plus OBT achieved viral load reduction to below 50 copies/mL compared to 33% of those receiving placebo plus OBT (p<0.001). Increases in CD4 cell counts from baseline were 83 and 31 cells/mm³ for subjects receiving Isentress and placebo, respectively (p<0.001).

    BENCHMARK-2
    This trial enrolled subjects in North, Central and South America. The mean baseline viral load was 4.7 log10 copies/mL for both the Isentress and placebo groups. The mean CD4 cell counts were 146 cells/mm3 for the Isentress group and 163 cells/mm3 for the placebo group. In BENCHMARK-2, 77% of subjects receiving Isentress in combination with OBT achieved HIV RNA viral load reduction to below 400 copies/mL compared to 43% of subjects receiving placebo plus OBT (p<0.001). In addition, 62% of subjects receiving Isentress plus OBT achieved RNA viral load reduction to below 50 copies/mL compared to 36% of those receiving placebo plus OBT (p<0.001). Increases in CD4 cell counts from baseline were 86 and 40 cells/mm³ for the subjects receiving Isentress and placebo, respectively (p<0.001). Treatment was generally well tolerated in both trials.

    Side Effects

    Adverse events associated with the use of Isentress may include, but are not limited to, the following:

    • Diarrhea
    • Nausea
    • Headache
    • Pyrexia
    • Asthenia
    • Fatigue
    • Dizziness
    • Acquired Lipodystrophy

    Mechanism of Action

    Isentress is an orally available human immunodeficiency virus integrase strand transfer inhibitor. Inhibition of integrase prevents the covalent insertion, or integration, of unintegrated linear HIV-1 DNA into the host cell genome preventing the formation of the HIV-1 provirus. The provirus is required to direct the production of progeny virus, so inhibiting integration prevents propagation of the viral infection.

    Literature References

    Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; the Protocol 004 Part II Study Team Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study. Journal of acquired immune deficiency syndromes 2007 Oct 1;46(2):125-133

    Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Merschman SA, Strohmaier KM, Ramael S, Lasseter KC, Stone JA, Gottesdiener KM, Wagner JA Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects. Clinical pharmacology and therapeutics 2007 Aug 22

    Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD; Protocol 005 Team Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007 Apr 14;369(9569):1261-9

    Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. Journal of acquired immune deficiency syndromes 2006 Dec 15;43(5):509-15

    Additional Information

    For additional information regarding Isentress or HIV, please visit the Isentress web page.

    Approval Date: 2007-10-01
    Company Name: Merck
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing